Please enable Javascript
CNS
CD19-Specific CAR-T Therapy Shows Promise in B-Cell ALL with CNSL
Leah Sherwood
Acute Lymphoblastic Leukemia
|
November 16, 2022
Treatment produced an overall response rate of 87.5% in those with BM disease and a 85.4% remission rate in those with CNSL.
Read More
Advertisement
Advertisement
Advertisement